Journal of Oncology Pharmacy Practice最新文献

{"title":"Cross-cultural adaptation to Brazilian Portuguese of the Indication for Common Toxicity Criteria Grading of Peripheral Neuropathy Questionnaire.","authors":"Leonardo Teodoro de Farias, Pryscila Rodrigues Moreira, Aline Dos Santos Iwasse, Luana Clara de Souza, Raíra Macário Silvério, Lunara Teles Silva, Tatyana Xavier Almeida Matteucci Ferreira, Renato Sampaio Tavares, Ana Carolina Figueiredo Modesto","doi":"10.1177/10781552251358347","DOIUrl":"https://doi.org/10.1177/10781552251358347","url":null,"abstract":"<p><p>BackgroundMultiple myeloma (MM) is a common hematological malignancy, and chemotherapy-induced peripheral neuropathy (CIPN) is one of its most significant adverse drug reactions. While CIPN can be managed through dose adjustments or treatment discontinuation, its assessment relies on patient-reported symptoms. The need for validated tools to accurately assess CIPN and support clinical decisions is critical to improving patient outcomes and ensuring more effective management strategies.AimTo perform the cross-cultural adaptation of the Indication for Common Toxicity Criteria Grading of Peripheral Neuropathy Questionnaire (ICPNQ) to Brazilian Portuguese.MethodThe cross-cultural adaptation process was conducted in five stages: (a) translation, (b) synthesis of translations, (c) submission of the translated version to a panel of experts, (d) pre-testing with the target population, and (e) back-translation into the original language.ResultsThe translation team included a specialist in onco-hematology, and the adapted version of the ICPNQ was evaluated by 20 healthcare professionals (nurses, pharmacists, and physicians) with an average of 9.5 years of experience in onco-hematology. The Content Validity Index (CVI) of the overall instrument was 0.98, while the CVIs for presentation and clarity were 0.98, and 0.97 for applicability. A pilot test was performed with 22 patients with MM in a specialized outpatient clinic for onco-hematological diseases in a university hospital. The patients were predominantly male (54.55%), over 65 years (59.09%), and using at least one neurotoxic drug (81.82<b>%).</b> Back-translation confirmed the semantic and cultural equivalence of the instrument's items.ConclusionThe Brazilian Portuguese version of the ICPNQ demonstrates semantic, idiomatic, cultural, and conceptual equivalence, suitable for application in the Brazilian context.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251358347"},"PeriodicalIF":1.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to Audit on Oral Systemic Anti-Cancer Therapies (SACT) Adherence Using the Morisky Medication Adherence Scale (MMAS): Implications for Pharmacy Counselling.","authors":"","doi":"10.1177/10781552251347796","DOIUrl":"https://doi.org/10.1177/10781552251347796","url":null,"abstract":"","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251347796"},"PeriodicalIF":1.0,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment duration of immune checkpoint inhibitors and overall survival in U.S. veterans with Cancer.","authors":"Sanya Z Hassan, Marshall J Tague, Mark A Klein, Brian C Lund","doi":"10.1177/10781552251357811","DOIUrl":"https://doi.org/10.1177/10781552251357811","url":null,"abstract":"<p><p>BackgroundOptimal treatment duration for immune checkpoint inhibitors (ICI) remains a clinical debate. The objective of this study was to contrast mortality rates between 2-year fixed versus indefinite treatment duration among patients initiating ICIs across a variety cancer types.MethodsThis retrospective observational study used national administrative data from the Veterans Health Administration to select patients who initiated an ICI between January 1, 2014, and December 31, 2020. ICI treatment duration was categorized as either fixed (2 years; 700-760 days) or indefinite (>760 days). A multivariate Cox proportional hazards regression model was used to examine the impact of duration on overall mortality.ResultsOf 1357 patients who received ICI treatment for at least 2 years, the probability of survival after 1 year was significantly lower in the fixed duration group (78.9%) compared to the indefinite duration group (87.6%; χ² = 12.6; df = 1; p < 0.001). At 2 years follow-up overall survival was not significantly different between groups (70.9% fixed vs. 76.5% indefinite; χ² = 3.5; df = 1; p = 0.061). In a multivariable Cox proportional hazards regression model, the adjusted HR for death for fixed versus indefinite duration groups was 1.22 (95% CI: 0.96-1.54), which did not reach statistical significance.ConclusionWhile failing to demonstrate a statistically significant difference, these findings suggest the potential for a clinically meaningful difference in mortality risk between fixed versus indefinite duration ICI treatment. These findings support the need for further research to determine the optimal duration for ICI treatment, and highlight weighing risks of mortality, immune-related adverse events, and financial cost.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251357811"},"PeriodicalIF":1.0,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144608619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mosunetuzumab-associated fatal HHV-6 encephalitis in a patient with follicular lymphoma.","authors":"Victor M Samperio, Moza Hamoud, Constantin A Dasanu","doi":"10.1177/10781552251355433","DOIUrl":"https://doi.org/10.1177/10781552251355433","url":null,"abstract":"<p><p>IntroductionMosunetuzumab is a CD3×CD20 bispecific antibody approved for relapsed/refractory follicular lymphoma. Although it was shown to achieve high response rates and durable remissions, immunosuppression with its use can be significant. Immune effector cell-associated neurotoxicity syndrome (ICANS) has been described with bispecific T-cell engager (BiTE) therapies, but human herpesvirus-6 (HHV-6) encephalitis has not been previously reported.CaseWe describe a 76-year-old woman with grade 3A follicular lymphoma treated with mosunetuzumab for twelve weeks. Ten days after the 4th cycle, she was admitted to the hospital with gradual onset of confusion and generalized weakness. Magnetic resonance imaging (MRI) showed bilateral mesial temporal T2/FLAIR hyperintensities. Cerebrospinal fluid (CSF) polymerase chain reaction (PCR) testing revealed HHV-6 infection.Management and outcomeICANS was initially suspected, and dexamethasone 10 mg IV daily was started. Following positive PCR testing for HHV-6, IV ganciclovir was commenced. Despite aggressive antiviral treatment, the patient's condition deteriorated and she died on hospital day 12.Discussion/conclusionSymptomatic HHV-6 reactivation has been recorded in the setting of allogeneic stem cell transplant and chimeric antigen receptor (CAR) T-cell therapy. This is the first instance of HHV-6 encephalitis associated with mosunetuzumab. The case underscores the importance of early CSF analysis and neuroimaging in patients with encephalopathy receiving T-cell-engaging therapies.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251355433"},"PeriodicalIF":1.0,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overcome Daratumumab' severe reaction with desensitization in relapsed multiple myeloma.","authors":"Trang L Nguyen, Truc Phan, Mai T Vu, Kn Vy Huynh, Yi Hyeon Gyu, Tuan D Nguyen, Lan Q Phan, Tuan D Nguyen, Dinh V Nguyen","doi":"10.1177/10781552251356918","DOIUrl":"https://doi.org/10.1177/10781552251356918","url":null,"abstract":"<p><p>IntroductionDaratumumab, a monoclonal antibody that specifically targets the myeloma cells' CD38 antigen, is promisingly used in both monotherapy and combination therapy for relapsed patients with multiple myeloma. However, this approach had a significant challenge due to the high rate of infusion-related reaction in the first dosage (up to 38%) despite strict instructions on infusion rate and dilution volume. This study describes a patient who overcame severe infusion reaction after the first dosage by desensitization.Case reportA 60-year-old man with multiple myeloma was relapsed with multiple bone damage and elevated immunoglobulin D lambda after VTD (bortezomid, thalidomide, dexamethasone) regimen completion. After 60 min of initial Daratumumab dose with sufficient pre-medication, the patient manifested suspected grade 3 infustion reaction and was transported to the intensive care unit.Management and outcomeDaratumumab was immediately terminated; <b>adrenaline,</b> methylprednisolone, and diphenhydramine were started. Another regimen was performed. However, due to substantial progression of symptoms, a re-introduction of daratumumab was considered. Daratumumab prick and intradermal skin test was performed with negative result. Desensitization were sucessfull with the number of bags and steps gradually lowered with no adverse events observed. After three cycles, the patient achieved VGPR (Very Good Partial Response) without any symptomatic spinal cord compression.ConclusionDesensitization is a promising solution to overcome daratumumab's severe infusion reaction, opening the new approach for clinicians. To ensure success, it is important to have a multidisciplinary team with experienced allergist, hematologist, Intensive Care Init (ICU) team and oncology pharmacist to create a safe environment for desensitization.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251356918"},"PeriodicalIF":1.0,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HER2-targeted agents and interstitial lung disease: A real-world pharmacovigilance analysis using FAERS data.","authors":"Huahua Zhang, Yandong Zhang, Xiaoying Wang, Jiangfeng Wang","doi":"10.1177/10781552251356906","DOIUrl":"https://doi.org/10.1177/10781552251356906","url":null,"abstract":"<p><p>IntroductionThere has been a growing concern regarding the interstitial lung disease (ILD) associated with HER2-targeted agents. This study aimed to elucidate the risk and characteristics of ILD associated with anti-HER2 agents using the FDA Adverse Event Reporting System (FAERS).MethodsData from 2004 Q1 to 2024 Q2 were extracted from the FAERS. The significant association between HER2-targeted agents and ILD was evaluated using the reporting odds ratio (ROR). Risk factors for mortality and time-to-onset were also assessed.ResultsA total of 2262 cases of HER2-targeted agents-associated ILD were identified. Positive signals were detected in trastuzumab deruxtecan (T-Dxd) (ROR = 31.28, 95% confidence interval [CI] 29.22-33.48), trastuzumab emtansine (T-DM1) (ROR = 6.27, 95% CI 5.38-7.32), pertuzumab (ROR = 6.08, 95% CI 5.36-6.89), trastuzumab (ROR = 4.02, 95% CI 3.73-4.33), tucatinib (ROR = 1.84, 95% CI 1.25-2.71), and lapatinib (ROR = 1.37, 95% CI 1.12-1.68). However, only two cases of ILD were associated with neratinib. The overall median time-to-onset was 75.5 days (interquartile range: 27.0-163.0). Logistic regression analysis revealed that elderly patients, treatment with T-Dxd, and treatment for non-breast cancer were significant risk factors for fatal outcomes related to ILD associated with HER2-targeted agents.ConclusionThis study suggests a significant association between the ILD and HER2-targeted agents, including T-Dxd, T-DM1, pertuzumab, trastuzumab, tucatinib, and lapatinib.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251356906"},"PeriodicalIF":1.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rhabdomyolysis induced by darolutamide and rosuvastatin.","authors":"E H Lee, N E Gogolin, M M Charpentier","doi":"10.1177/10781552251356456","DOIUrl":"https://doi.org/10.1177/10781552251356456","url":null,"abstract":"<p><p><b>Introduction:</b> Darolutamide is a second-generation nonsteroidal androgen receptor antagonist approved for treatment of castrate-resistant, nonmetastatic prostate cancer and metastatic hormone-sensitive prostate cancer. <b>Case report:</b> A mid-70s man with castration-resistant prostate cancer was initiated on darolutamide. Due to impaired renal function and a history of poor tolerance to previous chemotherapy, the patient was started at 300 mg per day with a plan to titrate to the recommended renal-adjusted dose. He was admitted to the hospital for complaints of lower extremity weakness during week 11 of treatment. Physical examination and imaging did not indicate any significant pathology from cancer or other medical conditions causing his symptoms. The pharmacist identified and reported a significant drug interaction between darolutamide and rosuvastatin. <b>Management & Outcome:</b> The suggested change was rosuvastatin discontinuation. Limiting the rosuvastatin dose to 5 mg is recommended during concomitant use with darolutamide. Since the patient had been receiving rosuvastatin 40 mg daily, he was potentially receiving five times the maximum dose. Considering the patient's complaints of myalgia and a marked elevation in creatine phosphokinase, his condition confirmed the diagnosis of rosuvastatin-darolutamide-induced rhabdomyolysis. Clinical symptoms improved and creatinine phosphokinase (CPK) elevation subsided following rosuvastatin cessation. <b>Discussion:</b> Darolutamide inhibition of breast cancer resistance protein (BCRP), organic anion-transporting polypeptides (OATP), and other protein transporters impacts clearance of substrate drugs to varying extents. Clinical relevance of inhibition depends on the extent to which affected proteins and transporters contribute to the clearance of the substrate. Rosuvastatin's significant reliance on BCRP for active efflux leads to an elevated risk of statin-associated muscle symptoms when co-administered with darolutamide.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251356456"},"PeriodicalIF":1.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to Suzetrigine: A potential alternative for palliative pain management in Pakistan's opioid-restricted healthcare system.","authors":"","doi":"10.1177/10781552251355823","DOIUrl":"https://doi.org/10.1177/10781552251355823","url":null,"abstract":"","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251355823"},"PeriodicalIF":1.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the potential relationship between antineoplastic agents and their association with stomatitis and oral candidiasis in cancer patients.","authors":"Ali Amanati, Robbert Van Manen, Laleh Mahmoudi, Hafez Shojaadini, Seyed Reza Abdipour Mehrian, Mohadese Boroughani","doi":"10.1177/10781552251354840","DOIUrl":"https://doi.org/10.1177/10781552251354840","url":null,"abstract":"<p><p>BackgroundAntineoplastic agents can cause oral toxicity, including \"antineoplastic agents-associated stomatitis\" (AAS) and \"antineoplastic agents-associated oral Candidiasis\" (AAOC), in children, adults, and older cancer patients.ObjectiveTo identify the risk of AAS and AAOC associated with using antineoplastic agents.MethodsThe FDA FAERS database for spontaneously reported adverse effects of \"antineoplastic agents\" was searched and analysed for the occurrence of the MedDRA preferred term \"stomatitis\" and \"oral Candidiasis\" using \"quantitative safety signal analysis\", which contains spontaneous safety reports collected from 1976 to the end of 2021.ResultsThe results of stomatitis in 27477 and oral candidiasis in 3136 case reports from the FDA database, which received antineoplastic agents during the treatment process. Among all three age groups studied, 4 and 7 antineoplastic agents were strongly associated with the occurrence of AAOC and AAS, respectively (reported odds ratio [ROR] > 100), and the lowest association with AAOC and AAS was reported in 19 and 33 antineoplastic agents, respectively (ROR < 1).ConclusionThere are several limitations to providing information on the side effects of new antineoplastic agents in drug databases. Signal detection in pharmacovigilance is a process in which safety issues, including possible drug-related side effects, are investigated. Our study highlights the gap in the database regarding the potential risk of AAOC and AAS, as reported by the FDA for new drugs.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251354840"},"PeriodicalIF":1.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144553800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of social determinants of health on primary adherence to oral oncolytic medications.","authors":"Nikki Uyehara, Valerie Nguyen, Stacey Yu, Sheila Haidar, Priyanka Patneedi, Yingjie Weng, Ashley Son, Elizabeth Oyekan, Neera Ahuja","doi":"10.1177/10781552251353724","DOIUrl":"https://doi.org/10.1177/10781552251353724","url":null,"abstract":"<p><p>IntroductionOral oncolytic medications have transformed cancer treatment, yet adherence to these therapies remains a significant challenge. This study aims to investigate the impact of social determinants of health (SDOH)-including access to basic necessities, health literacy, and social support- on primary adherence to oral oncolytic medications within a specialty pharmacy population of a large quaternary academic medical center.MethodsThis retrospective study assessed patient characteristics and medication adherence data taken from patients' electronic health records, as well as SDOH barriers from a self-reported patient questionnaire. Using multivariable logistic regression, the presence of SDOH barriers and their impact on oral oncolytic adherence were assessed.ResultsWhen assessing the association between patient characteristics and the presence of any SDOH barriers, patients who had a non-English primary language had 25.9 higher odds of reporting an SDOH barrier compared to patients whose primary language was English (95% CI: 3.6 to 579, p = 0.007). When assessing associations between individual SDOH categories and oral oncolytic primary adherence rate, patients who identified no health literacy barriers had 2.14 higher odds of filling their prescribed oral oncolytic medication(s) compared to patients who did identify barriers in health literacy (95% CI: 1.02 to 4.52, p = 0.044).ConclusionThis study highlights the impact of social determinants of health on medication adherence in a specialty pharmacy population, especially in relation to language and health literacy. The results may inform healthcare providers and policymakers in developing comprehensive support systems to optimize medication adherence for patients receiving oral oncolytic therapies.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251353724"},"PeriodicalIF":1.0,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}